Edgar Filing: VIDA JULIUS A - Form 4

VIDA JUL Form 4										
September						OMB A	PPROVAL			
FOR	VI 4 UNITED				E COMMISSION					
Check (this box	W	Washington, D.C. 20549			Number:	3235-0287			
if no lo subject Section Form 4 Form 5	nger to STATEN 16. or		SECURI	TIES	WNERSHIP OF	Expires: Estimated burden hou response	ed average nours per			
obligati may co <i>See</i> Inst 1(b).	ions Section 17(Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								
(Print or Type	e Responses)									
1. Name and VIDA JUI	Address of Reporting LIUS A	Symbol		Ticker or Trading	5. Relationship of Reporting Person(s) to Issuer					
			AREX INC [-	(Che	ck all applicabl	x all applicable)			
(Last)	(First) (of Earliest Traı 'Day/Year)	isaction	X Director	104	% Owner			
	Δ INTL PHARM ΓΑΝΤS, 27 SACH	09/01/			Difficer (give below)	e title Oth below)	ner (specify			
	(Street)	4. If An	4. If Amendment, Date Original		6. Individual or Joint/Group Filing(Check					
GREENW	ICH, CT 06830	Filed(M	onth/Day/Year)		Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting					
		(7:-)			Person					
(City)	(State)	(Zip) Ta	ble I - Non-De	rivative Securities A	Acquired, Disposed o	of, or Beneficia	lly Owned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		TransactionA Code D	(A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Re	eport on a separate line	e for each class of see	curities benefic	ially owned directly	or indirectly.					
				information cont required to resp	spond to the collec tained in this form ond unless the for ntly valid OMB con	are not m	SEC 1474 (9-02)			
	Tab			red, Disposed of, or ptions, convertible	Beneficially Owned securities)					
1. Title of Derivative		nsaction Date 3A. I th/Day/Year) Exec	Deemed ution Date, if	4. 5. Numb TransactiorDerivati			7. Title and Amount of Underlying Securities			

Edgar Filing: VIDA JULIUS A - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5))	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 14.92	09/01/2009		D	18,00	0 (1)	05/16/2017	Common Stock	18,000	
Stock Option (Right to Buy)	\$ 9.84	09/01/2009		D	18,00	0 (2)	07/25/2015	Common Stock	18,000	
Stock Option (Right to Buy)	\$ 9.63	09/01/2009		D	2,500) (3)	05/21/2012	Common Stock	2,500	
Stock Option (Right to Buy)	\$ 7.91	09/01/2009		D	18,00	0 (4)	05/14/2018	Common Stock	18,000	
Stock Option (Right to Buy)	\$ 7.48	09/01/2009		D	14,00	0 (5)	07/22/2012	Common Stock	14,000	
Stock Option (Right to Buy)	\$ 5.59	09/01/2009		D	14,00	0 (6)	07/23/2013	Common Stock	14,000	
Stock Option (Right to Buy)	\$ 4.89	09/01/2009		D	18,00	0 (7)	08/10/2014	Common Stock	18,000	
Stock Option (Right to Buy)	\$ 3.72	09/01/2009		D	18,00	0 (8)	03/04/2019	Common Stock	18,000	
Restricted Stock Units	<u>(9)</u>	09/01/2009		D	3,16	<u>(10)</u>	(12)	Common Stock	3,161	
Restricted Stock	<u>(9)</u>	09/01/2009		D	6,72	<u>(11)</u>	(12)	Common Stock	6,721	

Units

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Relationships

VIDA JULIUS A C/O VIDA INTL PHARM CONSULTANTS 27 SACHEM ROAD GREENWICH, CT 06830

Signatures

(1)

(2)

Squibb.

Beth A. Behrend, Attorney-in-Fact 09/03/2009

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

X

Date

This option was canceled in the merger in exchange for a cash payment of \$19,530.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$110,970.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers

This option was canceled in the merger in exchange for a cash payment of \$15,937.50, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$145,620.00, representing the difference between the exercise
(4) price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$119,287.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$145,740.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$200,070.00, representing the difference between the exercise
price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$221,040.00, representing the difference between the exercise
price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

- (9) Each restricted stock unit represents a contingent right to receive one (1) share of Medarex, Inc. common stock.
- (10) This restricted stock unit was canceled in the merger in exchange for a cash payment of \$50,576.00, based on the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (11) This restricted stock unit was canceled in the merger in exchange for a cash payment of \$107,536.00, based on the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

Edgar Filing: VIDA JULIUS A - Form 4

(12) The restricted stock units vested ratably on each of the first, second and third anniversaries of the grant date and the receipt of the shares of common stock was deferred until the individual's retirment or separation of service from the Board.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.